Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- JMACCT to Determine Number of Patients Seen by Each Institution by Disease
September 5, 2005
- BUSINESS NEWS IN BRIEF
September 5, 2005
- New Regenerative Therapy Using Cell Sheets Reported: Dr Okano
September 5, 2005
- Merger Preparations Going Smoothly: Sumitomo Pharm.
September 5, 2005
- SMOs Expected to Outpace CROs in Future Growth: Seminar
September 5, 2005
- Takeda Preparing to Launch Rozerem in US
September 5, 2005
- R&D NEWS IN BRIEF
September 5, 2005
- REGULATORY NEWS IN BRIEF
September 5, 2005
- Fuji Biomedix Debuts on NSE's Centrex Market
September 5, 2005
- Manifestos Published by Major Political Parties
September 5, 2005
- Korosho to Start Model Project to Prevent Metabolic Syndrome
September 5, 2005
- Insurance Premium Must Be Main Financial Resource for Healthcare Services: Seminar
September 5, 2005
- 1st Hyperuricemia/Metabolic Syndrome Forum Stresses Importance of Reduction in Multiple Risk Factors
September 5, 2005
- CDFS Recommends Approval of Candesartan for Chronic Heart Failure
September 5, 2005
- NEW PRODUCTD
September 5, 2005
- Institute Surveys Drug Expenditure Control Measures in 4 Major Countries
September 5, 2005
- PMDA Establishes Study Committee on Clinical Trials
September 5, 2005
- Current Gap Between NHI Prices and Market Prices 7-8%?
September 5, 2005
- NEW PRODUCTS
August 29, 2005
- 1st Half Business Results
August 29, 2005
ページ
Japan will overhaul its R&D tax credit regime in its FY2026 reform, introducing a new strategic category alongside existing frameworks.…
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…